Analysts at StockNews.com assumed coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock. 22nd Century Group Stock Performance XXII opened at $0.10 on Friday. The company’s 50 day moving average is $0.14 and […]